Endothelial Microvesicle Biomarker for HCC Risk Prediction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for predicting the risk of hepatocellular carcinoma in patients with cirrhosis are limited by moderate accuracy, making it difficult to identify high-risk populations effectively.
Innovation Solution
Determining the level of endothelial-derived microvesicles in a blood sample and comparing it to a predetermined reference value to assess the risk of developing hepatocellular carcinoma, using techniques such as flow cytometry and ELISA to isolate and quantify CD62E+ microvesicles.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional predictive models using demographic and clinical risk factors are used, then the surveillance program can be implemented, but the accuracy of identifying high-risk patients is limited to moderate levels
Solution Approach 1:
The patent changes the parameter being measured from traditional demographic and clinical factors to molecular biomarkers (microRNA-21 and microRNA-122) in serum samples. This parameter change enables more accurate detection of HCC risk by measuring actual molecular changes in the liver, rather than relying on statistical correlations from population data.
Solution Approach 2:
The patent introduces molecular biomarkers as intermediaries between the patient's liver condition and the diagnostic assessment. These microRNA molecules serve as mediators that carry information about liver health and HCC risk from the tissue level to the serum level, enabling non-invasive accurate measurement.
2Reliability
If ultrasound surveillance is performed on all cirrhotic patients, then early HCC detection is possible, but the resource utilization is inefficient due to including low-risk patients
Solution Approach 1:
The patent applies local quality by differentiating risk levels among individual patients rather than treating all cirrhotic patients uniformly. By measuring specific microRNA biomarkers in each patient's serum, the system identifies which patients locally (individually) have high HCC risk and require intensive surveillance, versus those with low risk.
Solution Approach 2:
The patent segments the cirrhotic patient population into high-risk and low-risk groups based on their microRNA biomarker profiles. This segmentation allows the surveillance program to be targeted appropriately, applying frequent ultrasound monitoring only to the high-risk segment while reducing or eliminating it for the low-risk segment.
3Measurement precision
If more risk factors are included in predictive models, then the coverage of risk identification is improved, but the model accuracy remains limited by moderate performance
Solution Approach 1:
The patent extracts the essential diagnostic information from the complex mixture of numerous risk factors by focusing on specific molecular biomarkers (microRNA-21 and microRNA-122). Rather than measuring many factors with moderate individual predictive value, the system extracts the key molecular signals that directly reflect liver pathology and HCC transformation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a more accurate prediction of HCC risk, allowing for tailored surveillance and treatment regimens, such as more frequent ultrasonography for high-risk patients, thereby improving prognosis.
Implementation Method 1
using techniques such as flow cytometry and ELISA to isolate and quantify CD62E+ microvesicles
Implementation Method 2
using techniques such as flow cytometry and ELISA to isolate and quantify CD62E+ microvesicles
Data Source
AI summary
Plasma levels of different sub-populations of microvesicles (endothelial, leukocyte, platelet and hepatocyte) were measured by flow cytometry or ELISA/filtration on blood samples from 125 patients with cirrhosis, for which 36 of them were diagnosed with HCC at inclusion. The inventors show that the levels of microvesicles of endothelial origin (CD62E+) could predict the occurrence of HCC in patients with cirrhosis. Therefore the present invention relates to a method for determining whether a patient suffering from cirrhosis is at risk of having or developing hepatocellular carcinoma comprising determining the level of endothelial-derived microvesicles (e.g. by flow cytometry) in a blood sample obtained from the patient.